Abigail Brooks, MA

Although FIB-4, ELF, and VCTE LSM performance did not vary significantly by patient characteristics, threshold adjustment was needed.

Garimella describes the overlap between diabetes and kidney disease, explaining the significance of semaglutide’s new indication for these patients.

The rolling NDA submission will include new data from the STARS Extend open-label extension study as well as data from the phase 3 STARS trial.

Findings suggest the benefits of combined belatacept and tacrolimus immunosuppression after kidney transplantation for patient and all-cause graft survival.

Study findings suggest NMP is especially beneficial for DCD allografts and is linked to better outcomes and resource use than SCS.

Findings suggest MASLD, especially with diabetes, overweight, or hypertension, is associated with significant fibrosis in patients with HCV.

The FDA approved semaglutide to reduce the risk of kidney disease worsening, kidney failure, and death due to CVD in those with T2D and CKD.

Patients who started dialysis as children but were not waitlisted until young adulthood faced worse outcomes than those who were listed before turning 18.

Compared with nonsurgical treatment, metabolic surgery was associated with reduced risks of incident MALO and progression to decompensation.

Results showed no difference in time to relapse, relapse rates, subsequent immunosuppression use, or kidney function between the medications.

Preliminary topline week 96 results showed statistically significant reversal of MASH compensated cirrhosis with efruxifermin in complete and ITT analyses.

Greater levels of physical activity and higher diet quality were linked to a reduced risk of MASLD, MetALD, and compensated advanced chronic liver disease.

Donor HCV positivity was not associated with acute rejection or recipient mortality 1-year post-renal transplant in HCV-negative recipients.

The updated clinical practice guideline addresses new research and clinical developments since the first iteration of the guideline was released in 2014.

Factors associated with 30-day readmission were shorter hospital stays after transplant, insurance status, and patient history of diabetes and malignancy.

MASLD and MetALD were linked to a greater risk of incident IBD, with risk increasing as the number of associated cardiometabolic risk factors increased.

The approval of Amneal Pharmaceuticals’ generic version of rifaximin 550 mg oral tablets is tentative due to the product’s involvement in litigation.

Abelacimab achieved notably lower levels of free factor XI and fewer bleeding events than standard-of-care rivaroxaban in the Phase 2b trial.

Findings point to global increases in alcohol use disorder, alcohol-associated liver disease, and liver cancer attributable to alcohol from 2000-2021.

Findings highlight the wide variety of outcomes experienced by patients with IgAN and the limited insights offered by clinical data at diagnosis.

Phosphatidylethanol outperformed several indirect blood-based alcohol biomarkers for differentiating MetALD from MASLD.

Study findings point to the prognostic value of anti-ETAR and anti-CXCR3 antibodies in IgA nephropathy and lupus nephritis.

The Breakthrough Therapy designation comes just months after positive phase 2 data for brelovitug were presented at AASLD The Liver Meeting in 2024.

The analysis of NHANES data revealed higher LE8 scores for cardiovascular health were linked to a decreased risk of MASLD.

Findings show differences in the clinicopathological characteristics and prognosis of patients with IgAN and nephrotic syndrome across renal pathologies.

In the absence of effective treatments, the prevalence of MASLD could reach 41.4% by 2050 and lead to large increases in HCC cases and liver transplants.

Dubinsky describes the evolution from anti-TNF therapies to IL-23 antagonists and the significance of mirikizumab’s approval for Crohn’s disease.

The study leverages large US-based claims datasets and pathologist input to estimate the annual incidence and total prevalence of IgAN in the US.

In a validated microsimulation model, annual CRC screening with FIT was the most cost-effective strategy among patients with low adherence.

Based on NHANES data, the age-adjusted prevalence of lean SLD was found to be 12.8%, including a 9.8% prevalence of lean MASLD.